Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, March 22, 2023
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
[ Wed, Mar 22nd 2023
] - WOPRAI
Brian Abrahams Reiterated (XENE) at Buy and Held Target at $51 on, Mar 22nd, 2023
Brian Abrahams of RBC Capital, Reiterated "Xenon Pharmaceuticals Inc." (XENE) at Buy and Held Target at $51 on, Mar 22nd, 2023.
Brian has made no other calls on XENE in the last 4 months.
There are 4 other peers that have a rating on XENE. Out of the 4 peers that are also analyzing XENE, 0 agree with Brian's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Brian
- Serge Belanger of "Needham" Maintained at Strong Buy with Increased Target to $50 on, Thursday, March 2nd, 2023
- Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $60 on, Wednesday, December 14th, 2022
- Joseph Thome of "Cowen & Co." Initiated at Buy on, Monday, December 12th, 2022
- Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $50 on, Monday, November 28th, 2022
